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Abstract: Protein accumulation has been identified as a characteristic of many degenerative conditions, 
such as neurodegenerative diseases and aging. In most cases, these conditions also present with 
diminished protein degradation. The ubiquitin-proteasome system (UPS) is responsible for the 
degradation of the majority of proteins in cells; however, the activity of the proteasome is reduced 
in these disease states, contributing to the accumulation of toxic protein. It has been hypothesized 
that proteasome activity, both ubiquitin-dependent and -independent, can be chemically stimulated 
to reduce the load of protein in diseased cells. Several methods exist to identify and characterize 
stimulators of proteasome activity. In this review, we detail the ways in which protease activity can 
be enhanced and analyze the biochemical and cellular methods of identifying stimulators of both the 
ubiquitin-dependent and -independent proteasome activities. 
Keywords: proteasome; stimulation; fluorescent probes; 20S CP 
1. Introduction 
One of the most basic, essential cellular processes is the degradation of proteins. This primarily 
occurs through two pathways: degradation by lysosomes, also known as autophagy, or degradation by 
the proteasome [1,2]. The proteasome degrades proteins using two systems, the ubiquitin-dependent 
(UPS) and the ubiquitin-independent (UIPS) proteasome systems, Figure 1A [3,4]. The UPS utilizes 
the 26S proteasome isoform, which is comprised of a 19S regulatory particle (19S RP) and a 20S 
core particle (20S CP). The 19S RP is responsible for recognizing a ubiquitinated substrate, removing 
ubiquitin, unfolding the substrate, and shuttling it into the 20S CP. The physical association of the 
19S RP to the 20S CP causes a conformational change in the α-ring of the 20S CP to allow the protein 
substrate to enter for hydrolysis [5]. The 20S CP is composed of four heptameric rings in the order 
α, β, β, α. The α-subunits form the gate of the 20S CP, which prevents well-folded proteins from 
entering the hydrolysis chamber of the 20S CP without a regulatory particle present [6]. The β-rings 
of the 20S CP each house three catalytic subunits, β1, β2, and β5, which correspond to the following 
hydrolysis activities: caspase-like, trypsin-like, and chymotrypsin-like, respectively. The UPS requires 
a system of proteins to polyubiquitinate substrates that are recognized and degraded by the 26S 
proteasome. A well-characterized pathway in which the UPS plays a critical role is the endoplasmic 
reticulum-associated protein degradation (ERAD) system [7,8]. ERAD focuses on the degradation of 
misfolded proteins, and many disease states characterized by ER stress are correlated with a decrease in 
UPS activity [9,10]. The UIPS, on the other hand, cannot degrade ubiquitinated substrates. This system 
utilizes the 20S CP for the degradation of intrinsically disordered or oxidatively damaged proteins that 
become unfolded [11,12]. These proteins are capable of entering the gate of the 20S CP without the 
presence of the 19S RP to initiate a conformational change of the α-ring. However, the UIPS can make 
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use of other regulatory particles, such as the 11S RP, which can cause a similar conformational change 
of the α-ring to expedite substrate entry [13]. 
Figure 1. (A) Overview of the ubiquitin-proteasome system (UPS) and the ubiquitin-independent 
proteasome system (UIPS). The UPS utilizes a set of E-ligases to polyubiquitinate protein substrates for 
recognition and degradation by the 26S proteasome. The UIPS employs the 20S core particles (20S CP), 
which can be capped or uncapped by the 11S regulatory particle (11S RP), to degrade oxidatively 
damaged and intrinsically disordered proteins. (B) In the presence of pro-inflammatory signals, such as 
interferon-gamma (IFN-γ), the catalytic subunits of the standard 20S CP (sCP) can become exchanged 
for the catalytic subunits of the immunoproteasome (iCP). 
In healthy cells, the UPS and UIPS are both working to help alleviate the load of damaged proteins 
or proteins that have served their purpose and need to be degraded. In healthy, young fibroblasts, 
the 26S proteasome isoform only accounts for approximately 21 to 35% of proteasome isoforms in 
the cell [14]. The remaining percentage is comprised of the 11S RP-capped 20S CP and free 20S CP, 
which is the primary isoform, accounting for two-thirds of the proteasome population. In immune 
cells and cells exposed to pro-inflammatory signals, the standard 20S CP can become exchanged for the 
immunoproteasome, Figure 1B [15]. The immunoproteasome is structurally identical to the standard 
20S CP, except for the catalytic subunits, which are exchanged for the β1i, β2i, and β5i [16]. These 
subunits have different hydrolysis activities than the standard 20S CP, resulting in alternative cleavage 
sites of protein substrates. The immunoproteasome produces peptides capable of being loaded into 
MHC-I complexes to alert the immune system of an infection. 
Many disease states have been characterized by an accumulation of protein, leading to 
proteotoxicity. Diseases, such as Alzheimer’s, Parkinson’s, aging, Huntington’s, and amyotrophic 
lateral sclerosis, exhibit a diminished ability of cells to maintain proper proteostasis [17–23]. This is due, 
in part, to reduced activity of the proteasome. In the majority of these diseases, this phenomenon is the 
result of a lack of expression of subunits composing the 19S RP, increasing the amount of free 20S CP, or 
both the 19S RP and 20S CP, decreasing the total quantity of proteasomes in the cell [24]. Because this 
is a shared characteristic of many disease states, developing a method to enhance proteasome activity, 
either 26S or 20S CP, to reduce protein accumulation has become a prominent area of research. Multiple 
studies have found that increased proteasome activity is beneficial, decreasing the accumulation of 
oxidized protein and delaying aging [25–27]. Enhancing proteasome activity can be accomplished 
through genetic manipulation of subunit expression, such as overexpressing the β5 subunit of the 20S 
CP or Rpn-6 of the 19S RP, or through peptide or small molecule stimulation [26,28–30]. Chemical 
stimulators are commonly grouped into two categories: gate-openers, which modulate the α-ring 
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of the 20S CP to enhance substrate entry, and allosteric modulators of the hydrolysis activity, which 
can impact at least one of the activities performed by the catalytic β-subunits. Several peptides or 
small molecule stimulators of the proteasome have been identified by a few different research groups, 
and the methodology to detect and characterize proteasome stimulators is an evolving field [31–43]. 
In this review, we describe and assess various current techniques used to discover and evaluate small 
molecule stimulators of the proteasome. 
2. Discovery: Biochemical High-Throughput Screening Assays 
Initial efforts to discover proteasome stimulators are often performed using high-throughput 
biochemical screens. These methods use purified proteasome and monitor proteasome activity through 
co-incubation with a substrate (Figure 2A–C). In this section, we will review the different techniques 
used to monitor proteasome activity and describe how these methods can also be used to extrapolate a 
general mechanism of stimulation of a “hit” molecule. 
Figure 2. Summary of the biochemical methods often used to identify proteasome stimulators. 
(A) Fluorogenic substrates produce a fluorescent signal following substrate hydrolysis. (B) Analysis 
of the degradation of peptide substrates can be performed using mass spectrometry. The first peak 
in the spectra corresponds to the full peptide. The second peak corresponds to the degradation 
product containing the fmoc protecting group. (C) Evaluating degradation of a specific protein by the 
proteasome can be performed using SDS-PAGE analysis. 
2.1. Fluorogenic Peptide Substrates 
Since the discovery of the proteasome in 1983, fluorogenic peptide substrates have been used to 
monitor its activity. In the initial discovery, Wilk and Orlowski used peptides’ three amino acids in 
length containing either a p-nitroanilide (pNA) or a 2-napthylamide (2NA) on the C-terminus [44]. 
The peptides used were specific to the three protease activities exhibited by the proteasome. Following 
the cleavage after the third amino acid residue, the pNA or 2NA group would fluoresce. Monitoring 
this fluorescence over time allows one to assess proteasome activity. Since 1983, many more fluorogenic 
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commonly used employ a 7-amino-4-methylcoumarin (AMC) group on the C-terminus. This group has 
a higher degree of fluorescence over pNA or 2NA and therefore, provides a more effective readout [46]. 
Table 1 lists the fluorogenic peptide substrates commonly used today and the corresponding hydrolysis 
activity of the proteasome. 
Table 1. Common fluorogenic peptide substrates used to assess proteasome activity. 










Non-specific cleavage FRET reporter 
The majority of these substrates are small (3–4 amino acids in length) and can easily fit past 
the gate of the 20S CP to be hydrolyzed, allowing for efficient measurement of activity. Multiple 
studies that have identified proteasome stimulators have utilized Suc-LLVY-AMC [32,34–36,38–41]. 
By plotting the change in fluorescence of AMC over time, one can obtain a “rate” of hydrolysis. This 
“rate” is used to compare a sample containing a tested small molecule to a control sample to determine 
if there is an increase or decrease in activity. Small molecules and peptides discovered as stimulators of 
the proteasome using this method are shown in Figure 3A. 
Figure 3. (A) Structures of small molecule and peptide stimulators discovered using Suc-LLVY-AMC 
to monitor proteasome activity. All except betulinic acid are believed to act as gate-openers of the 20S 
CP. Betulinic acid has been shown to enhance only the chymotrypsin-like activity of the β5 subunit. 
(B) Structures of small molecules determined to be proteasome stimulators using the fluorescence 
resonance energy transfer (FRET) reporter. All except the triazine derivative are gate-openers of the 
20S CP. The triazine derivative enhances a β-subunit catalytic activity, although the precise subunit 
is unknown. 
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A more recently developed reporter of proteasome activity utilizes fluorescence resonance energy 
transfer (FRET) technology to produce a fluorescent signal [33]. This reporter is larger than the 
commonly used AMC reporters and contains the FRET pair, Edans and Dabcyl. While the peptide 
is intact, FRET occurs between the pair, producing only a minimal fluorescent signal that does not 
change over time. However, once the peptide is hydrolyzed, the distance between the FRET pair 
increases, producing a much greater fluorescent signal. Similar to the AMC reporters, this signal can be 
monitored over time to assess proteasome activity. This reporter is not specific to any of the hydrolysis 
activities of the proteasome and was developed to be similar to a protein-like substrate. Due to its 
size, it does not easily fit into the hydrolysis chamber of the 20S CP. Characterization of this reporter 
revealed that it is more sensitive to 20S CP stimulation than the Suc-LLVY-AMC substrate. Figure 3B 
shows the stimulating small molecules discovered using the FRET reporter [33,42]. 
2.2. Mass Spectrometry Substrate Analysis 
Another effective method for identifying stimulators of proteasome activity involves the use of 
mass spectrometry (Figure 2B). First developed by Trader et al., this method employs an N-terminally 
Fmoc-protected peptide substrate that is incubated with or without the proteasome for a certain 
period of time [34]. The sample is then quenched and run on a mass spectrometer to identify and 
quantitate the full peptide and the cleavage product(s). This provides the basal level of activity of 
the proteasome. If a small molecule is included in the incubation for testing, quantitation of the full 
peptide and cleavage product(s) from the chromatogram can reveal whether this molecule has any 
effect on proteasome activity. For this assay, the Fmoc group is kept on the N-terminus of the substrate 
to facilitate retention of the peptide on the reverse-phase column. This allows for the full peptide 
and the cleavage product containing the N-terminus to be easily identified and quantified on the 
chromatogram. For normalization, results between samples are compared by assessing the ratio of 
cleaved product to the whole peptide. This value was used to compare samples and determine the 
extent of increased proteasome activity induced by a small molecule. 
2.3. Gel-Based Assays 
The methods described to this point utilize peptide substrates to assess proteasome activity. 
Many times, small molecule enhanced degradation of a peptide substrate does not directly translate 
to enhanced degradation of a protein. Gel-based assays have been developed to monitor protein 
substrate degradation by the proteasome (Figure 2C) [32–35]. These assays utilize purified proteins, 
both proteasome and substrate. The protein substrate is incubated (1) by itself, (2) with the proteasome, 
and (3) with the proteasome and a small molecule. The samples are then run on an SDS-PAGE gel and 
can either be stained with Coommassie, or an immunoblot can be performed to visualize the protein 
substrate. Imaging and subsequent quantitative analysis are then performed to determine how much 
of the substrate is degraded by the proteasome in the absence and presence of the small molecule. 
It is important to obtain a standard curve of the protein substrate before performing this assay to 
indicate the limit of detection of that particular substrate when used for an immunoblot or stained with 
Coommassie. The amount of proteasome used will also need to be optimized to prevent the presence 
of the proteasome from interfering with substrate quantitation of a Coommassie-stained gel. This 
assay is useful to determine how much more of a particular protein can be degraded in the presence of 
a small molecule stimulator, but it can also be used to assess a rate of degradation if performed for 
different time periods. Kinetic analysis using this assay can be a very beneficial characterization of a 
small molecule stimulator of the proteasome. 
2.4. General Mechanism of Small Molecule Stimulators 
All of the assays described above can be used as primary or secondary screening to either identify 
or validate a small molecule stimulator of the proteasome (any isoform). Because these assays can 
be used with either the 20S CP, the 26S proteasome, or the immunoproteasome, repeating the assay 
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with the other isoforms can provide an indication of the mechanism of stimulation. In theory, small 
molecule stimulators can act through two separate mechanisms: (1) gate-openers, which stabilize a 
more gate-opened state of the 20S CP (or iCP), or (2) an allosteric modulator, impacting at least one of 
the hydrolysis activities [33]. Gate-opening small molecules should not have any effect on the activity of 
the 26S proteasome, as the gate is occupied by the 19S RP. These types of stimulators should, however, 
still maintain a stimulatory effect with the immunoproteasome, which has a gate structurally identical 
to that of the 20S CP. A molecule that is able to directly impact one of the hydrolysis activities will also 
have this effect on the 26S proteasome but will likely not affect the immunoproteasome. Because the 
immunoproteasome contains different catalytic subunits, an allosteric modulator of β1, β2, or β5 of 
the 20S CP should not impact β1i, β2i, or β5i of the immunoproteasome. However, these subunits 
maintain a high percentage of structural similarity, so an impact on activity may still be observed [16]. 
Of the two general mechanisms, allosteric modulators are less common and less understood. 
There is evidence that some allosteric modulators may have different impacts on the various hydrolysis 
activities. For instance, Ritonavir, a known human immunodeficiency virus-1 protease inhibitor, 
was shown to inhibit the chymotrypsin-like activity while enhancing the trypsin-like activity of the 
proteasome [47,48]. This type of impact could indicate multiple binding sites; however, further 
structural studies are necessary to understand the mechanism behind this allosteric modulator. 
3. Discovery: In Vitro Assays 
Following the identification and validation of small molecule proteasome stimulators, cellular 
assays are often performed to determine the efficacy of these stimulators in a cell model. Such assays 
provide information on cell permeability and target specificity, both of which are important for a 
potential therapeutic approach and for understanding the overall impacts of stimulating the proteasome. 
In this section, we review the cellular assays most commonly used to assess proteasome stimulators 
and discuss assays that have been used to monitor proteasome activity, which could be used to 
evaluate stimulators. 
3.1. GFP-Fusion Protein Assay: 20S CP Stimulator 
Stimulators of the 20S CP are often examined using a green fluorescent protein (GFP)-fusion 
protein (Figure 4) [32,34,35]. Cell lines suitable for transfection are transfected to express a known 
substrate of the 20S CP that has been fused to GFP. Common protein substrates include α-synuclein, 
tau, and ornithine decarboxylase. This assay is effective at monitoring 20S CP-mediated degradation, 
as the uncapped 20S CP can degrade the unstructured portion of the GFP-protein fusion, leaving 
an increased amount of free, intact GFP, whereas the 26S proteasome can degrade the entire fusion 
protein. The transfected cells can be treated with a 20S CP stimulator to be compared to a control 
sample. The time of treatment is dependent on the toxicity of the molecule; however, most studies 
using this assay are performed using a 24-hr treatment period. Following treatment, the cells are lysed, 
and a Western blot is performed, looking specifically at GFP. The analysis is performed by quantitating 
the bands corresponding to the fusion protein and free GFP. The ratio of free GFP to the fusion is 
calculated for the treated sample and compared to the control to determine the increased activity of the 
20S CP. One of the necessary assumptions of this assay is that the activity of the 26S proteasome is 
consistent across all samples. Because the 26S proteasome will degrade the entire fusion protein and 
the free GFP that is produced by 20S CP activity, it is important that the activity of the 26S proteasome 
is the same across all samples. This assay can effectively be used once it is determined that the small 
molecule does not impact 26S proteasome activity. 
Western Blot l Quantitation 
• GFP-a-synuclein ~ 
FreeGFP ~ 
Cell Transfection 
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Figure 4. General procedure of evaluating a 20S CP stimulator in cells using a GFP-α-synuclein 
fusion protein. 
3.2. Analysis of Endogenous Protein Levels 
Evaluating the impact of a proteasome stimulator on the degradation of an endogenous protein can 
often be difficult to assess due to ongoing protein synthesis. To more easily detect enhanced degradation, 
many studies have employed cycloheximide, a protein synthesis inhibitor [49]. Cycloheximide exerts 
its effects by inhibiting translational elongation in eukaryotes, making it a useful tool to evaluate 
the degradation of proteins. Often, cycloheximide is used to determine the half-life of a particular 
protein [50]. This is accomplished by treating cells with cycloheximide for various time periods and 
performing a Western blot for that protein to see at what point the band disappears. Cycloheximide 
is the most commonly used agent for these purposes; however, protein synthesis inhibition by 
cycloheximide is not 100% efficient. The transcription inhibitor α-amanitin is a potent protein synthesis 
inhibitor and can be used as a substitute [51]. 
When using cycloheximide, or any protein synthesis inhibitor, to evaluate a proteasome stimulator, 
the endogenous protein of interest is often one that is already known to be degraded by at least 
one isoform of the proteasome. For example, α-synuclein is a known substrate of the 20S CP and is 
commonly used to evaluate the impact of a 20S CP stimulator in neuronal cells [34]. When performing 
an experiment to look at endogenous protein, it is important to understand which isoforms of the 
proteasome will be impacted. This can be done using the biochemical assays mentioned above. 
To analyze stimulators of the 26S proteasome, it can be beneficial to look at the ubiquitinated form of 
the protein of interest. Substrates of the 26S proteasome are polyubiquitinated for recognition by the 
19S RP [52]. Therefore, it can be helpful to analyze the ubiquitinated protein levels when evaluating 
protein degradation by the 26S proteasome. Analysis of endogenous protein levels can be performed 
by Western blot. 
4. Methods to Monitor Proteasome Activity in Cells 
4.1. GFP-Fusion Protein Assay: 26S Proteasome Stimulator 
GFP-fusion proteins have also been specifically designed to monitor 26S proteasome 
activity [53–56]. These proteins are typically used to analyze overall UPS activity or to evaluate 
inhibitors of the 26S proteasome. However, these GFP-constructs may also have the potential to be 
used as tools to measure 26S proteasome stimulation in cells using small molecules. The most effective 
constructs for this purpose would be the GFPU construct, which is GFP fused to a sixteen amino 
acid CL1 degron, or the UbV-GFP fusion, which contains a mutated, non-cleavable ubiquitin fused to 
GFP [53,55]. The presence of the degron in GFPU enhances the recognition and degradation of this 
protein in cells. A similar phenomenon occurs with the UbV-GFP protein, as the presence of ubiquitin 
induces polyubiquitination and causes more efficient degradation. These proteins could be used in 
a kinetic fluorescence assay to monitor the decrease in GFP fluorescence over time. In the presence 
of a 26S proteasome stimulator, it would be expected that GFP signal would decrease at a faster rate. 
However, these proteins may be degraded too quickly by the non-stimulated 26S proteasome to be 
adequately used in this context, requiring the use of a more stable construct. 
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For a longer study that would involve cell treatment with a stimulator for several hours, a GFP 
fusion that is less susceptible to degradation would be required. GFP is naturally a very stable protein 
and is not an efficient substrate of the UPS [53]. Therefore, GFP mutants have been created that are not 
as stable as native GFP, yet still have a longer half-life than the proteins mentioned above. One such 
fusion would be Ub-L-GFP, which utilizes the N-end rule to prevent quick degradation of GFP, yet is 
not as stable as the native M-GFP.53 The N-end rule suggests that having an arginine or an amino acid 
residue that is readily acetylated as the N-terminal residue enhances the recognition and degradation 
of that protein [57]. By replacing the methionine with a leucine as the N-terminal residue, GFP becomes 
destabilized and is more readily degraded by the UPS. This fusion protein could be a useful tool for 
the analysis of a 26S proteasome stimulator to determine enhanced degradation of Ub-L-GFP when the 
stimulator is present. 
4.2. Radioactively Labeled Proteasome Substrates 
One of the ways in which researchers study the rate of protein degradation by the proteasome is to 
use a radioactively labeled amino acid, such as [H3] phenylalanine ([H3]-Phe) [58]. By exposing cells to 
[H3]-Phe, this amino acid becomes incorporated into proteins. Varying the length of exposure allows 
for the monitoring of short-lived or long-lived proteins. The labeled proteins will then be degraded by 
either the proteasome or the lysosome, producing short peptides that are further degraded by other 
proteases into individual amino acids. The cells are then incubated with a large excess of non-labeled 
Phe to prevent reincorporation of the labeled amino acids into newly synthesized proteins. This also 
encourages the excretion of the labeled amino acids into the medium, as the non-labeled Phe is taken 
into the cells. For the evaluation of short-lived proteins, cycloheximide is included in the medium 
supplemented with the non-labeled Phe to prevent protein synthesis and allow for immediate analysis 
without a long incubation time. Following incubation with the non-labeled amino acid, aliquots of the 
medium can be taken at different time periods. The medium should contain the degradation products 
of proteins that have been excreted from the cell. To ensure that only degradation products are present, 
trichloroacetic acid (TCA) is added to the medium to precipitate any proteins. This solution can then 
be centrifuged to separate the precipitated proteins from the degradation products, which will remain 
in the supernatant. Once the aliquots of the medium have been removed from the plate, the cells 
can be dissolved in a solution of NaOH. Both the supernatants containing the degradation products 
from various time periods and the cell lysate containing the labeled proteins are placed into separate 
scintillation vials. By measuring the amount of [H3]-Phe in each sample, one can determine the rate 
of total protein degradation. Performing an additional experiment of dosing with a proteasome or 
autophagy inhibitor allows for the calculation of how much protein degradation is due to each pathway. 
This method of analyzing proteasome activity has not been applied to a small molecule proteasome 
stimulator. However, such an experiment would provide information other assays fail to deliver. 
The method described above provides a proteasomal rate of degradation of cellular proteins, which 
is precisely what is impacted by a small molecule stimulator. Therefore, this assay could provide 
information pertaining to how the rate of protein degradation by the proteasome is affected by a small 
molecule stimulator in cells. Unfortunately, there is no way to differentiate degradation by the 26S 
proteasome versus the 20S CP, as the majority of proteasome inhibitors directly target the 20S CP. 
KDT-11 and RA-190 are known inhibitors of Rpn13, which is a ubiquitin-receptor of the 19S RP [59,60]. 
These inhibitors could potentially be used as a control to identify how much protein degradation is 
ubiquitin-independent. In addition, the majority of the proteins degraded by the 20S CP are known to 
be short-lived proteins, such as regulatory and signaling proteins [6,61]. Performing this experiment 
with a 20S CP stimulator to monitor short-lived proteins could provide a difference in the rate of 
degradation of these proteins. However, further experimentation is needed to determine whether this 
method could be useful in analyzing a stimulator of the 20S CP. 
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4.3. In Vitro Fluorogenic and Bioluminescent Reporters 
A few fluorogenic reporters have been developed to measure proteasome activity in cells, 
corresponding to the hydrolysis of the reporter [62,63]. One such reporter is referred to as the 
TED peptide, which stands for Tat-Edans-Dabcyl (Figure 5A) [62]. Ten amino acids from the 
transfer domain of the Tat protein were added to the C-terminus of this reporter to help with 
cell permeability [64]. The amino acid sequence between the FRET pair, Edans-Dabcyl, contains the 
LLVY cleavage-determining motif, with the intention of achieving specificity for the β-5 subunit of 
the 20S CP. Further lysine residues were added to the N-terminus of the peptide to ensure a net 
positive charge and promote membrane penetration. Analysis of this reporter revealed that the primary 
cleavage site is following the tyrosine; however, other cleavage products are also produced. Incubating 
the TED peptide with various cell lines produced an increase in fluorescence of Edans, associated with 
cleavage of the peptide by the proteasome. A maximum fluorescence signal was observed after 15 min 
of incubation. 
Figure 5. Structures of two fluorogenic reporters of proteasome activity that are effective in cells: 
(A) the Tat-Edans-Dabcyl (TED) peptide and (B) TBZ-1. 
Another reporter, TBZ1, published recently by Zerfas et al. is effective at selectively monitoring 
immunoproteasome activity in cells (Figure 5B) [63]. This reporter utilizes a rhodamine moiety for its 
source of fluorescence, following reporter hydrolysis, and a peptoid portion to increase cell permeability. 
Both TBZ1 and the TED peptide are able to monitor proteasome activity in cells in a kinetic fluorescence 
assay. Though these methods have not been applied to stimulators of any isoform of the proteasome, 
each offers an opportunity to directly monitor enhanced proteasomal activity in cells in the presence of 
a small molecule stimulator. 
In addition to these fluorogenic reporters, a similar way of assessing proteasome activity utilizes 
bioluminescent reporters [65]. These reporters are structurally based on the AMC fluorogenic reporters 
often used in biochemical assays to monitor the individual activities of the proteasome. Instead of 
having an AMC group on the C-terminus, this group is substituted for aminoluciferin, which can 
be utilized by luciferase to produce light. The amount of light produced is directly proportional 
to proteasome activity. These luminescent substrates can aptly measure the individual proteasome 
activities in cells, offering a unique tool to assess proteasome stimulators. 
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5. Structural Evaluation of Small Molecule Stimulators of the Proteasome 
5.1. AFM 
Atomic force microscopy (AFM) has been proven an effective method of identifying the various 
states of the 20S CP [66,67]. The gate of the 20S CP is formed by the N-termini of several α-subunits. 
In solution, the gate is able to flux between the open- and closed-state, with the majority of the 20S CP in 
the closed-state. AFM is able to determine the percentage of 20S CP in the open-or closed-state. Several 
small molecule stimulators of the 20S CP are believed to stabilize the open-gate conformation, which 
would increase the percentage of 20S CP in this state. Using AFM, several studies have been able to 
confirm the conformational changes associated with the binding of a small molecule stimulator [35,43]. 
In particular, the small molecule TCH-165 discovered by Njomen et al. was determined to increase the 
percentage of open-state 20S CP from 28% ± 4% in the control sample to 59% ± 3% in the presence of 
2 µM TCH-165 [35]. AFM has been shown to distinguish between these states of the 20S CP; however, 
the resolution using this technique is not high enough to determine specific structural elements. To look 
at amino acid structure and small molecule binding, a higher resolution technique, such as cryo-electron 
microscopy (cryo-EM), needs to be used. 
5.2. Cryo-EM 
Cryo-EM has been successfully used to determine the structure of the human 20S CP and the 26S 
proteasome in different conformational states, Figure 6 [68,69]. Using this technique to analyze the 
binding site of a small molecule stimulator can illuminate the binding pocket and the key amino acids 
necessary for binding. Cryo-EM can also identify structural conformational changes that occur as a 
result of small molecule binding. This information is important to understand what subunits can be 
impacted to influence proteasomal activity. Identifying the binding pocket and key interactions can 
lead to structure-activity-relationship (SAR) studies that modify the structure of the small molecule to 
better interact with the proteasome. 
Figure 6. Cryo-EM structure of the human singly-capped 26S proteasome. 
6. Conclusions 
The proteasome has been implicated as a potential target for stimulation in a number of disease 
states marked by protein accumulation. In this review, we discussed current methods of identifying 
and evaluating stimulators of various isoforms of the proteasome, such as high-throughput biochemical 
assays using fluorogenic substrates, cellular studies of GFP-fusion proteins, and structural experiments 
using AFM or cryo-EM. We also examined established methods of monitoring proteasome activity in 
cells that have the possibility of being used to analyze small molecule stimulators, which includes 
Molecules 2019, 24, 2341	 11 of 14 
cellular fluorogenic or bioluminescent assays and using radio-labeled substrates to assess degradation 
by the proteasome. 
Though the methods described here are effective at identifying stimulators of the proteasome, 
multiple assays are often required to (1) validate the small molecule as a proteasome stimulator, 
(2) determine the general mechanism of stimulation, and (3) assess the efficiency of the stimulator in 
cell models. The cellular assays used to this point are not high-throughput, requiring a significant 
amount of time and materials. It is, therefore, important to develop and apply more high-throughput 
cellular methods to identify and assess proteasome stimulators to directly evaluate their effectiveness 
in cell models. This would streamline the process of determining the therapeutic potential of a small 
molecule stimulator toward a protein accumulation disease. 
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